Press Releases

Date Title View
Toggle SummarySeptember 14, 2020 GenMark Diagnostics’ ePlex® Respiratory Pathogen Panel 2 (RP2) achieves CE Mark
Molecular syndromic test for COVID-19, influenza and other common respiratory pathogens helps health care professionals prepare for flu season RP2 Panel at a Glance GenMark’s ePlex® Respiratory Pathogen Panel 2 ( RP2 ) has achieved CE mark. RP2 provides results in less than two hours for more than
View HTML
Toggle SummaryAugust 17, 2020 GenMark Diagnostics Announces Submission of Emergency Use Authorization for its eSensor® SARS-CoV-2 Test
Leveraging GenMark’s eSensor XT-8® platform to expand COVID-19 diagnostic testing capacity CARLSBAD, Calif. , Aug. 17, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, announced that it has notified
View HTML
Toggle SummaryAugust 4, 2020 GenMark Diagnostics Reports Second Quarter 2020 Results
CARLSBAD, Calif. , Aug. 04, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (Nasdaq: GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced financial results for the quarter ended June 30, 2020 . Second Quarter 2020 Highlights Total revenue of
View HTML
Toggle SummaryJuly 29, 2020 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , July 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today announced that the company plans to participate in two upcoming investor conferences.
View HTML
Toggle SummaryJuly 21, 2020 GenMark Diagnostics to Report Second Quarter 2020 Financial Results on August 4, 2020
CARLSBAD, Calif. , July 21, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) today announced that it plans to release its second quarter earnings results after market close on Tuesday, August 4, 2020. Management will hold a conference call to review the company's financial
View HTML
Toggle SummaryJuly 7, 2020 GenMark Diagnostics Provides Preliminary Financial and Operational Results for Second Quarter 2020
Second Quarter 2020 Revenue Expected to Represent Approximately 118% Year-Over-Year Growth CARLSBAD, Calif. , July 07, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems, today provided preliminary
View HTML
Toggle SummaryJune 29, 2020 GenMark Diagnostics Announces Commercial Launch of its ePlex® Respiratory Pathogen Panel 2 (RP2)
Updated test provides rapid results for SARS-CoV-2 and other important respiratory pathogens and a simplified workflow CARLSBAD, Calif. , June 29, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular diagnostic testing systems,
View HTML
Toggle SummaryJune 16, 2020 GenMark Diagnostics Chosen as Primary Provider of Rapid Diagnostic Testing for Vidant Health
Largest health system in eastern North Carolina turns to ePlex® platform for fast results on SARS-CoV-2, respiratory and blood stream infections CARLSBAD, Calif. , June 16, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ:GNMK), a leading provider of automated, multiplex molecular
View HTML
Toggle SummaryMay 27, 2020 GenMark Diagnostics to Participate in Upcoming Investor Conferences
CARLSBAD, Calif. , May 27, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML
Toggle SummaryMay 11, 2020 GenMark Diagnostics Announces Closing of $80 Million Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
CARLSBAD, Calif. , May 11, 2020 (GLOBE NEWSWIRE) -- GenMark Diagnostics, Inc. (NASDAQ: GNMK) (“GenMark” or the “Company”), a molecular diagnostics company focused on developing and commercializing multiplex molecular diagnostic solutions designed to enhance patient care, improve key quality
View HTML